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Abstract
Background: The analysis of high-throughput gene expression data with respect to sets of genes
rather than individual genes has many advantages. A variety of methods have been developed for
assessing the enrichment of sets of genes with respect to differential expression. In this paper we
provide a comparative study of four of these methods: Fisher's exact test, Gene Set Enrichment
Analysis (GSEA), Random-Sets (RS), and Gene List Analysis with Prediction Accuracy (GLAPA).
The first three methods use associative statistics, while the fourth uses predictive statistics. We
first compare all four methods on simulated data sets to verify that Fisher's exact test is markedly
worse than the other three approaches. We then validate the other three methods on seven real
data sets with known genetic perturbations and then compare the methods on two cancer data
sets where our a priori knowledge is limited.
Results: The simulation study highlights that none of the three method outperforms all others
consistently. GSEA and RS are able to detect weak signals of deregulation and they perform
differently when genes in a gene set are both differentially up and down regulated. GLAPA is more
conservative and large differences between the two phenotypes are required to allow the method
to detect differential deregulation in gene sets. This is due to the fact that the enrichment statistic
in GLAPA is prediction error which is a stronger criteria than classical two sample statistic as used
in RS and GSEA. This was reflected in the analysis on real data sets as GSEA and RS were seen to
be significant for particular gene sets while GLAPA was not, suggesting a small effect size. We find
that the rank of gene set enrichment induced by GLAPA is more similar to RS than GSEA. More
importantly, the rankings of the three methods share significant overlap.
Conclusion: The three methods considered in our study recover relevant gene sets known to be
deregulated in the experimental conditions and pathologies analyzed. There are differences
between the three methods and GSEA seems to be more consistent in finding enriched gene sets,
although no method uniformly dominates over all data sets. Our analysis highlights the deep
difference existing between associative and predictive methods for detecting enrichment and the
use of both to better interpret results of pathway analysis. We close with suggestions for users of
gene set methods.
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Background
One of the major goals in oncology is determining biolog-
ical markers associated to onset, differentiation and pro-
gression of tumors, which could be potential targets for
therapies [1]. Traditionally this objective has been pur-
sued by a) measuring the expression levels of thousands
of genes simultaneously in two different phenotypic con-
ditions, and b) identifying those genes that are differen-
tially expressed between disease phenotypes. It is well
known that such an approach has serious limitations: the
obtained results are poorly reproducible in studies on the
same disease carried out in different laboratories; moreo-
ver much of the information associated to genes weakly
connected with the phenotype is lost due to the univariate
statistics usually adopted in these studies [2].
A common approach in expression analysis to overcome
some of these issues is to combine the expression data
with functionally or structurally related gene sets and
examine over or under representation of these genes [3]
with respect to genes that are differentially expressed. The
key application of this setting is to assay the deregulation
of sets of genes that encode functional or structural anno-
tations such as pathways or chromosomal regions with
respect to disease state. In this paper we use the terms
enriched and deregulated gene set interchangeably to
indicate gene sets statistically associated to the phenotype.
A variety of methods have been developed for assessing
the enrichment of sets of genes with respect to differential
expression between two phenotypes or experimental con-
ditions [2-9].
In this paper we present an empirical study to compare
four of the above methods for assaying gene set enrich-
ment. The methods we selected are Fisher's exact (FE) test
[3], Gene Set Enrichment Analysis (GSEA) [2], Random-
Set Methods (RS) [8] and Gene List Analysis with Predic-
tion Accuracy (GLAPA) [7]. These approaches are repre-
sentative of two distinct classes of methods to assess
deregulation of gene sets. The first three methods use asso-
ciative statistics and aim to quantify the deregulation of a
gene set by measuring differences between the distribu-
tions of the expression levels of the genes belonging to the
gene set in the two phenotypic conditions assayed. The
criteria for selecting these particular methods were FE is
the oldest method, GSEA is one of the most commonly
used methods, and RS is computationally one of the most
efficient methods. The fourth method uses a predictive sta-
tistic and quantifies the deregulation of a gene set by meas-
uring the prediction accuracy of the phenotype of new
subjects by using the expression levels of the genes in the
gene set. GLAPA is the only predictive method in the
above list.
The comparison of these four methods was carried out on
simulated and real expression data. A simulation study
was conducted in which we measured the ability of the
methods to detect deregulated gene sets in which the
deregulation is known by design. Moreover, we analyzed
the accuracy of these methods on real data where we have
strong a priori knowledge of which pathways or gene sets
we expect to be differentially enriched between pheno-
typic conditions. This requirement is satisfied a) by stud-
ies where a model system is genetically perturbed and a
gene set is defined as genes that most differentially express
under the perturbation, as well as b) by expression studies
where the pathways driving the phenotypic distinction are
known. We have collected nine data sets that satisfy this
requirement: five data sets with controlled genetic pertur-
bations used to generate oncogenic signatures [10], two
NCI-60 data sets where the phenotypic annotation
strongly suggests which pathways should be differentially
expressed, and data sets of breast and lung cancer [11,12]
where our prior knowledge is weaker and limited.
We find that the performance of FE test is strongly influ-
enced by the level of the test adopted to find differentially
expressed genes. This method is the least sensitive and is
shown to lack power. For these reasons it was excluded
from the successive analysis. The other three methods,
even though with substantial differences, are accurate and
recover relevant gene sets. The simulation study highlights
that no method outperforms all others consistently. In
particular, GSEA and RS, in order, are able to detect weak
one-sided deregulations. On the contrary, when up and
down-regulated genes belong to the same gene set RS per-
forms better than GSEA due to the particular statistics
adopted. GLAPA is more conservative and larger differ-
ences between the two phenotypes are required to allow
the method to detect deregulation of a gene set. The prop-
erties of the methods highlighted by the simulation study
are confirmed by the analysis of the methods on real data
sets. The activity of important oncogenes and pathways
known to be deregulated in the experimental conditions
and pathologies analyzed are detected although with dif-
ferent accuracy across the data sets. We find the ranking of
enrichment of gene sets induced by GLAPA and RS to be
very similar while GSEA produces somewhat different
rankings. The ranking induced by GSEA is more similar to
RS than GLAPA. Overall the rankings of all three methods
share significant overlap. The conservative nature of
GLAPA emerges in the analysis on real data and is due to
the fact that it is based on a predictive score.
In the discussion section we provide users of gene set
methods some practical advice on how to interpret the
results of gene set analysis based on the empirical study
we have conducted.BMC Bioinformatics 2009, 10:275 http://www.biomedcentral.com/1471-2105/10/275
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Methods
Data sets
Two different sets of data were used in our study (see
Table 1). The first set was relative to microarray gene
expression data in which the activity of particular onco-
genes or the deregulation of given pathways were known.
In [10], human primary mammary epithelial cell cultures
(HMECs) were used for studying in vitro pathways associ-
ated to the activation of Myc, Ras, E2F3, Src and β-catenin
oncogenes. To this end, recombinant adenoviruses were
used for expressing the activities of these oncogenes in an
otherwise quiescent cell and RNA from multiple inde-
pendent infections were collected for DNA microarray
analysis using Affymetrix Human Genome U133 Plus 2.0
Array. Each experiment was composed of gene expression
profiles of HMECs with activated oncogene and profiles
of HMECs expressing green fluorescent protein, GFP, as
control. Moreover we used a dataset with a known P53
perturbation from the NCI-60 collection of cancer cell
lines, profiled by using Affymetrix Human Genome U95
Array (hgu95av2). This dataset included 12 normal sam-
ples and 50 samples with a P53 mutation. Finally, we con-
sidered an expression data set composed of 3 human
astrocytes and 3 epithelial cells (HeLa cells) maintained
under hypoxic conditions and 3 human astrocytes and 3
HeLa cells maintained under normal conditions [13], pro-
filed by using Affymetrix Human Genome U133 Plus 2.0
Array. The second set of data was relative to microarray
gene expression data of real human tumors. In [11], gene
expression profiles were obtained for 60 individuals with
hormone receptor-positive primary breast cancer treated
with adjuvant tamoxifen monotherapy. Of these individ-
uals, 32 experienced tumor recurrence. In [12], patients
affected by non-small cell lung cancer (NSCLC) were pro-
filed by using Affymetrix Human Genome U133 Plus 2.0
Array. The dataset was composed of 45 adenocarcinoma
lung cancer samples and 48 squamous lung cancer sam-
ples.
All the data sets were properly normalized according to
the procedure adopted in their original papers. In particu-
lar, oncogene [10], P53 and lung [12] data sets were nor-
malized by using Robust Multiarray Average (RMA)
procedure; Hypoxia data set [13] was normalized by using
GCOS1.2 with the advanced PLIER (probe logarithmic
intensity error) algorithm; breast data set [11] was nor-
malized by using the robust nonlinear local regression
method proposed in [14].
Gene sets
The database of gene sets used in this paper was the
Molecular Signatures Database (MSigDB) [2]. This is a
collection composed of 1692 curated gene sets based on
high-throughput experiments as well as expert knowledge
from literature or databases. We added 10 gene sets to this
database that were defined in [15]. To compare the three
methods, we assessed the enrichment of all the gene sets
in the experimental conditions and diseases examined.
Algorithms
We are given a data set S = {(x1, y1), (x2, y2),..., (x, y)}
composed of  labelled specimens, where xi ∈ d, yi ∈ {-1,
1} for i = 1,2,..., and d is the number of probes on the
microarray in the adopted technology. Let us suppose we
have + positive and - negative examples, such that  = +
+ -. Moreover, we are given a gene set G = {g1, g2,..., gm}
composed of m probes, where m << d.
RS
Let si, i = 1,..., d, be a score associated to each probe. This
score is a quantitative measure of differential expression
which in our case is based on a two sample t-statistic for
each gene ti, the two samples are the two phenotypes or
conditions. Specifically, si = |Φ-1(( ti))|, i = 1,..., d, where
ti were the two-sample t-statistics values computed for
each gene,  (ti) = rank(ti)/d where rank(ti) is the rank of
the value ti in the array [t1,..., td], and Φ is the standard nor-
mal cumulative distribution function. Given these scores
the measure of gene set deregulation is Z = (  - μ)/σ,
where   is the average of gene scores,  ,
and μ = {}  a n d  σ = var{ } are easily computed from
the full set of gene scores.
Large values of Z are expected if G is deregulated in the
experimental conditions analyzed. P-values are computed
using phenotypic permutation test [16] and false discov-
ery rate (FDR) computations are provided using the
method described in [4].
GLAPA
This method uses an estimate of the generalization error
of predictors trained by using raw expression levels of the
ˆ F
ˆ F
X
X Xs m g gG =
∈ ∑
1
X X
Table 1: Data sets used in our experiments. The breast cancer 
data set is annotated by gene symbols.
Dataset Study Class I vs Class II # Probes
Myc [10] 10 vs 10 54675
Ras [10] 10 vs 10 54675
E2F3 [10] 9 vs 10 54675
Src [10] 7 vs 10 54675
β-catenin [10] 9 vs 10 54675
P53 NCI-60 12 vs 50 12625
Hypoxia [13] 6 vs 6 54675
Breast [11] 28 vs 32 15017
Lung [12] 45 vs 48 54675BMC Bioinformatics 2009, 10:275 http://www.biomedcentral.com/1471-2105/10/275
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genes belonging to G as a measure of enrichment of G [7].
Unbiased estimates of the generalization error were
obtained through multiple cross validation strategies
[17]. To this end, we build a reduced data set   composed
of  examples consisting only of probes corresponding to
the genes in G. The cross validation is implemented by
randomly splitting   into a pair ( ,  ) of training and
test sets with h and k examples respectively,  = h + k. A lin-
ear classifier is trained using the examples in   and its
error rate ei was evaluated by testing the classifier on  .
The random splitting of   was repeated 200 times and the
error rate eG associated to G was evaluated as the average
of ei, i = 1,..., s. The assessment of the statistical signifi-
cance of the measured eG was carried out by two inde-
pendent permutation tests.
The first test (T1) controls for how likely the error rate eG
was due to chance and we performed 1000 random per-
mutations of the phenotypic label to compute this p-
value. The second permutation test (T2) controls for the
effect of the gene set size in the error rate eG and is per-
formed by randomly selecting gene sets of the same size as
G and recomputing eG. We used 1000 random gene sets to
compute this p-value. The FDR in each permutation test
was estimated with the method described in [4].
GSEA
This method uses a variation of a Kolmogorov-Smirnov
statistic to provide an enrichment score for each gene set.
Although numerous and more sophisticated variants of
this method exist (see for example [18]), we refer to the
original work of Subramanian [2]. This version of the
methodology uses a variation of rank statistics where the
ranks are weighted by the absolute value of the associa-
tion of gene expression with phenotype, the weighting is
added to overcome the granularity of rank based methods
- there is a loss of sensitivity. As in the random set method
a score measuring the correlation of a probe with the phe-
notype is required, si, i = 1,..., d. We use the signal-to-noise
metric in the standard GSEA setting as our score.
This metric is very similar to the two sample t-statistic
used in our implementation of RS. Based on these corre-
lation scores and the adjusted Kolmogorov-Smirnov sta-
tistic we compute an enrichment score which is signed.
The weighting parameter in the adjusted Kolmogorov-
Smirnov statistic is the absolute value of the correlation
statistic, this is also the default parameter in the distrib-
uted software. Negative scores correspond to down-regu-
lation of the gene set and positive scores correspond to
up-regulation of the gene set. These enrichment scores are
then normalized to take into account the size of the gene
sets resulting in a normalized enrichment score. This nor-
malization is done based on phenotypic permutations
followed by standardization, see [2]. P-values as well as
false discovery rates are computed using the standard set-
ting of the software.
Simulation study
The performances of the various methods used in the
paper were assessed through a simulation study in which
the amount of deregulation and the number of differen-
tially expressed (DE) genes in a gene set were known by
design. To this end, we adopted the same scheme sug-
gested in [9] and simulated 1000 genes and 50 samples in
each of 2 classes, control and treatment. The genes were
assigned to 50 gene sets, each with 20 genes. All measure-
ments were generated as No(0,1) before the treatment
effect was added. There were five different scenarios:
1. all 20 genes of gene set 1 are 0.2 units higher in class
2;
2. the 1st 15 genes of gene set 1 are 0.3 units higher in
class 2;
3. the 1st 10 genes of gene set 1 are 0.4 units higher in
class 2;
4. the 1st 5 genes of gene set 1 are 0.6 units higher in
class 2;
5. the 1st 10 genes of gene set 1 are 0.4 units higher in
class 2, and 2nd 10 genes of gene set 1 are 0.4 units
lower in class 2.
In every scenario only the first gene set is of potential
interest. For each scenario, we repeated 20 simulations
and, for every simulation, we carried out 1000 permuta-
tions of the phenotypic labels to compute the p-value of
RS and GSEA and the p-value1 of GLAPA, and we used
1000 random gene sets with 20 genes to compute the p-
value2 of GLAPA. The mean and standard error of the p-
values computed over the 20 simulations are reported in
Table 2.
We extended the simulations to study the effect of heavier
tails and dependence between genes in the gene set. To
model heavier tails we used the Student's t-distribution to
generate the measurements. To model dependence
between genes we used the normal distribution with
strong positive covariance to generate measurements. Nei-
 S
 S  Dh  Th
 Dh
 Th
 SBMC Bioinformatics 2009, 10:275 http://www.biomedcentral.com/1471-2105/10/275
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ther of these variations resulted in appreciable differences
in the simulation results (see Table 1 and 2 in Additional
file 1).
Unlike the other three methods a threshold is required to
select a subset of significantly DE genes when using
Fisher's exact test. We used a t-test with specified α to
select the set of genes of which we measure the overlap
with genes in the gene sets. The simulation results for var-
ious levels of α are presented in Table 3. Comparing the
simulation results of Fisher's exact test versus the other
three methods (see Table 2) illustrates the lack of power
of this approach. This test is unable to detect gene sets
with modest deregulation and its performance is strongly
influenced by the level α adopted to find DE genes. For
these reasons we excluded the Fisher's exact test in the
comparisons in the results section.
The simulation study on the other three methods high-
lights that no method outperforms all others consistently.
In particular, GSEA and RS are able to detect weak dereg-
ulations between control and treatment groups, as long as
the percentage of DE genes in the gene set is greater than
50% as in the first three scenarios. Note that the perform-
ances of RS increase as the amount of deregulation of the
gene set increases. Their performances decrease when only
the 25% of the genes belonging to the gene set are DE as
in the 4th scenario. Finally, as the 5th scenario shows, RS
performs better than GSEA when a two-sided deregulation
in opposite directions occurs in the same gene set. This
property is due to the particular score function adopted in
RS which uses the absolute value. On the contrary, the
amount of deregulation strongly influences the perform-
ances of GLAPA. Large differences are required between
the two groups to allow GLAPA to detect deregulation of
a gene set. Moreover, differently from RS and GSEA, this
method is poorly influenced by the percentage of DE
genes in the gene set. In fact, as the 4th scenarios shows,
GLAPA is able to detect the deregulation even whether
only the 25% of the genes is DE in the gene set. This prop-
erty is particularly relevant when we assess the statistical
significance of the deregulation in the second permuta-
tion test T2 in which the error rate of the gene set is com-
pared with the error rate of random gene sets with the
same size. These two aspects highlight the conservative
nature of this method.
Results
Comparison of the three methods can be summarized in
terms of three aspects: validation of the gene set methods,
differences in gene set ranks across the methods, and dif-
ferences due to associative versus predictive scores.
Table 2: Results of simulation study: comparison of RS, GSEA and GLAPA. P-values for the first gene set for the three methods 
(columns) and five different scenarios (rows) described in the text.
RS GLAPA GSEA
P-value P-value1 P-value2 P-value
mean se mean se mean se mean se
1 0.0177 0.0069 0.0678 0.0135 0.0173 0.0057 0.0002 0.0001
2 0.0005 0.0002 0.0152 0.0036 0.0007 0.0003 0.0002 0.0001
3 0.0004 0.0002 0.0064 0.0026 0.0003 0.0002 0 0
4 0.0126 0.0081 0.0073 0.0025 0.0002 9e-05 0.0166 0.0044
5 0 0 0.0001 8e-05 0 0 0.0877 0.0151
Table 3: Results of simulation study: Fisher's exact test. 
α = 0.01 α = 0.02 α = 0.03 α = 0.04 α = 0.05
P-value P-value P-value P-value P-value
mean se mean se mean se mean se mean se
1 0.4117 0.0901 0.2789 0.0773 0.1509 0.0411 0.1243 0.0406 0.1137 0.0427
2 0.1961 0.0795 0.0342 0.0171 0.0270 0.0217 0.0287 0.0265 0.0140 0.0120
3 0.0085 0.0033 0.0019 0.0011 0.0024 0.0010 0.0034 0.0020 0.0053 0.0034
4 0.0030 0.0017 0.0016 0.0006 0.0039 0.0018 0.0081 0.0037 0.0113 0.0039
5 2e-04 0.0002 1e-06 0 1e-06 0 6e-07 0 7e-07 0
P-values for the first gene set in the five different scenarios (rows) described in the text. In each column we report the significance level (α) adopted 
in t-test to find DE genes.BMC Bioinformatics 2009, 10:275 http://www.biomedcentral.com/1471-2105/10/275
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The measure of evidence of enrichment for a gene set is
the Z score for RS, the absolute value of the normalized
enrichment score (NES) for GSEA, and the cross-valida-
tion error eG in GLAPA.
Validation of the three algorithms
For each of the gene sets we have some prior knowledge
of which gene sets should be deregulated. For some of the
data sets such as the P53, Hypoxia, and the five oncogenic
perturbations we have very strong knowledge of which
gene sets should be deregulated since the genetic pertur-
bation is very controlled. In the lung cancer and breast
cancer data there are many genetic perturbations and
these are not controlled samples. However, due to prior
biological knowledge we still have some weaker expecta-
tions of which gene sets should be deregulated.
For validating the three methods we define for each data
set a core set composed of gene sets thought to be
involved in biological or cellular processes relevant in a
data set. The reason for considering the core set as a whole
is that gene sets are constructed under a variety of contexts
and conditions and looking at a group of sets helps aver-
age out this variation. In addition to providing evidence
for the enrichment and significance of individual gene
sets we provide a summary statistic of the enrichment of
the core set as well as the significance of this summary.
The summary we use in this paper is the median rank of
the gene sets in the core set and we use a permutation pro-
cedure much like a sign-rank test to assess significance.
P53 perturbation data
The NCI-60 collection of cancer cell lines contains 50
samples with P53 mutation and 12 normal samples. We
expect to find enrichment of gene sets corresponding to
pathways associated with P53 mutation in this data set.
P53 is a tumor suppressor gene involved in the apoptotic
signaling circuitry. In particular, the P53 protein is a tran-
scription factor that normally inhibits cell growth and
stimulates cell death when induced by cellular stress [19].
The results of the three methods applied on the whole
MSigDB gene set collection are reported in Additional
file 2.
In MSigDB we found 12 gene sets associated at varying
levels to P53 deregulation. These defined our core set, see
Table 4. This core set is composed of P53 gene sets as well
as P21, hypoxia, and BRCA1 gene sets. P21 is relevant
since it is a downstream effector of P53 that mediates both
G1 and G2/M phase arrest and may be induced during
P53-mediated apoptosis [20]. BRCA1 is involved in p53-
mediated growth suppression [21]. Hypoxic conditions
elicit P53 overexpression and consequent apoptosis.
As Table 4 shows collectively the core set is strongly dereg-
ulated with respect to P53 mutation. The median scores
are 67, 63, and 27.5 for RS, GLAPA, GSEA respectively and
these are all significant p < 0.001. We ordered the gene sets
according to the mean rank over the three methods in
Table 4 and found the top six (in bold) to be highly
ranked across all methods with median scores for this sub-
set of 9.5, 10.5, and 4.5 for RS, GLAPA, and GSEA. One
observation is that when P53 signatures were split into
up-regulated and down-regulated sub-signatures the
down-regulated gene sets were not consistently enriched.
This is clearly illustrated by comparing the
KANNAN_P53_UP and KANNAN_P53_DN signatures.
Indeed five of the gene sets with low or mixed ranks cor-
respond to P53 sub-signatures of down-regulation.
In summary the three methods are consistent across the
twelve core gene sets and six of these accurately represent
P53 mutation status.
Table 4: Results for the P53 gene sets in the Wild-Type/P53 mutant data set.
RS GLAPA GSEA
Pathway Size Rank P-value Rank P-value1 P-value2 Rank P-value
STRESS_P53_SPECIFIC_UP 17 2 0.000 3 0.004 0.000 2 0.000
P53GENES_ALL 30 4 0.000 9 0.013 0.000 8 0.000
P53PATHWAY 41 10 0.000 10 0.019 0.000 5 0.000
KANNAN_P53_UP 52 9 0.001 11 0.018 0.000 6 0.000
P53HYPOXIAPATHWAY 38 21 0.001 15 0.022 0.000 4 0.000
P53_BRCA1_UP 40 137 0.068 66 0.084 0.008 1 0.000
P53_SIGNALING 163 59 0.023 60 0.075 0.000 203 0.063
P21_P53_EARLY_DN 14 75 0.103 619 0.348 0.329 47 0.017
P21_P53_ANY_DN 46 470 0.294 1212 0.548 0.736 66 0.067
P21_P53_LATE_DN 11 661 0.357 1218 0.527 0.650 454 0.323
P21_P53_MIDDLE_DN 21 1381 0.744 1243 0.544 0.683 440 0.307
KANNAN_P53_DN 25 1478 0.893 1015 0.476 0.569 944 0.548BMC Bioinformatics 2009, 10:275 http://www.biomedcentral.com/1471-2105/10/275
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Hypoxia data
The hypoxia data set is composed of 6 samples under
hypoxic conditions and 6 samples under normal condi-
tions. Hypoxia refers to the condition a cell experiences
under oxygen deficiency. In this conditions, numerous
adaptive responses are activated at molecular and cellular
level, including alteration of gene expression. Alterna-
tively, cancer cells can genetically elicit a hypoxic response
in the setting of normal oxygen levels to activate new
blood vessel formation to experience a growth advantage.
The results of the three methods applied on the whole
MSigDB gene set collection are reported in Additional file
3. In MSigDB we found 19 gene sets associated at varying
levels to hypoxia. These defined our core set, see Table 5.
In addition to hypoxia gene sets these core gene sets con-
tained Vascular endothelial growth factor (VEGF) gene
which is generally up-regulated by hypoxic conditions
and promotes normal blood vessel formation and angio-
genesis related to tumor growth. In addition, hypoxia up-
regulates the von Hippel-Lindau tumor suppressor gene
(VHL) which plays a key role in VHL-hypoxia-inducible
factor (VHL-HIF) pathway [22].
As Table 5 shows collectively the core set is strongly dereg-
ulated with respect to hypoxia. However we see greater
variation in the median scores across the methods than in
the case of P53. The median scores are 15, 130, and 31 for
RS, GLAPA, GSEA respectively and these are all significant
p < 0.001. As in the P53 case we ordered the gene sets
according to the mean rank over the three methods in
Table 5 and found the top eleven (in bold) to be highly
ranked across all methods with median scores for this sub-
set of 7, 42, and 9 for RS, GLAPA, and GSEA.
In summary there is still strong agreement across the three
methods even though the variation in this data set is
greater than that of the P53 example. We are not sure
whether this is due to the much smaller sample size or
greater biological variability in the induction of hypoxia.
When we restrict ourselves to the nine highly ranked gene
sets the variability is comparable to the P53 case.
Oncogenic pathways
In [10] five data sets were generated by activating the fol-
lowing five oncogenes Myc, Ras, E2F3, Src, and β-catenin
in human primary mammary epithelial cell cultures. As a
control GFP was also activated in these cell cultures. For
each data set a signature of oncogenic deregulation was
generated, for example a Myc, Ras, E2F3, Src, and β-cat-
enin signatures. We took each signature and split them
into up and down-regulated signatures based on whether
the genes correlated with the Myc phenotype or the GFP
phenotype.
We added these 10 gene sets to those in MSigDB. In this
case the core gene sets for each data set are the correspond-
ing two up and down regulated gene sets. For example, in
the Ras data set we expect the up and down-regulated gene
sets to rank towards the top.
We applied the three methods for measuring enrichment
of the extended gene set database in these five data sets.
Table 5: Results for the Hypoxia gene sets in the Hypoxia/normal data set.
RS GLAPA GSEA
Pathway Size Rank P-value Rank P-value1 P-value2 Rank P-value
MENSE_HYPOXIA_UP 342 1 0.000 19 0.074 0.000 2 0.000
HYPOXIA_FIBRO_UP 51 3 0.000 18 0.081 0.004 9 0.000
MENSE_HYPOXIA_DN 14 31 0.000 1 0.054 0.000 4 0.000
MANALO_HYPOXIA_UP 305 11 0.001 30 0.083 0.000 7 0.004
MENSE_HYPOXIA TRANSPORTER_GENES 196 7 0.003 42 0.083 0.000 11 0.002
MENSE_HYPOXIA APOPTOSIS_GENES 38 10 0.000 31 0.086 0.000 26 0.014
HYPOXIA_NORMAL_UP 587 4 0.000 64 0.086 0.000 6 0.000
HIF1_TARGETS 98 8 0.004 66 0.088 0.006 37 0.013
HYPOXIA_REVIEW 220 5 0.002 116 0.111 0.005 8 0.000
VEGFPATHWAY 85 38 0.001 135 0.093 0.016 59 0.011
HYPOXIA_REG_UP 105 2 0.002 241 0.128 0.037 29 0.010
MANALO_HYPOXIA_DN 211 133 0.178 253 0.125 0.032 126 0.094
HIFPATHWAY 42 49 0.018 611 0.196 0.142 31 0.008
P53HYPOXIAPATHWAY 57 285 0.070 249 0.120 0.053 238 0.126
VHL_NORMAL_UP 1251 26 0.083 328 0.134 0.008 522 0.081
RCC_NL_UP 1529 15 0.033 239 0.116 0.001 727 0.222
VHL_RCC_UP 288 374 0.188 130 0.118 0.003 539 0.229
HYPOXIA_RCC_NOVHL_UP 159 528 0.201 177 0.111 0.014 560 0.260
HYPOXIA_RCC_UP 330 716 0.304 415 0.136 0.092 561 0.177BMC Bioinformatics 2009, 10:275 http://www.biomedcentral.com/1471-2105/10/275
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The rank of the respective up/down gene set for each
oncogenic perturbation is reported in Table 6. A complete
description of the results obtained on these data sets is
reported in Additional file 4, Additional file 5, Additional
file 6, Additional file 7 and Additional file 8. In this case
the three methods were not similar and GSEA seems to be
much better at highlighting the respective pathway dereg-
ulation. We suspect the reason that GLAPA does not rank
the deregulated pathway as strongly as GSEA is that in
these oncogenic perturbations a multitude of pathways
are deregulated. For example in the Ras data set the cross-
validation prediction error for the two Ras gene sets are e
= 0.0 with very small p-values (p-values .007 and .004 for
Ras up and down). However, GLAPA measured an error
rate of 0.0 for 70% of the gene sets and these estimates
also had very small p-values, < 0.01. This situation also
occurs in the other data sets. This suggests that perturba-
tion of the oncogenes results in deregulation across many
pathways and deep functional changes.
The point of this example is that when the difference
between the two phenotypes is extensive and character-
ized by a wide variety of pathways or gene sets, GLAPA
and RS may not be able to focus on the most deregulated
pathways while GSEA, at least in this example, finds these
gene sets.
Breast cancer
The deregulation of the whole MSigDB collection was
measured in the breast cancer data set composed of
patients with recurrent and non recurrent phenotypes
[11]. We compared the three methods in detecting dereg-
ulation of some pathways related to these phenotypes.
The first gene set we considered was the P53 pathway. This
pathway is in general altered in many types of cancers [1]
and its importance as a marker for recurrence in breast
cancer is well known [23]. GLAPA detected a strong dereg-
ulation of P53_BRCA1_UP pathway (rank = 2, P-value1 =
0.009, P-value2 = 0.001) and this finding was confirmed
by RS (rank = 8, P-value = 0.002).
A further analysis concerned the cell cycle deregulation.
This pathway has been identified as one of the hallmarks
of cancer [24] and, more important, an increased activity
of the cell cycle has been linked to more aggressive tumors
[25]. GSEA was the only method which highlighted the
deep alteration of CELL_CYCLE_CHECKPOINT pathway
(rank = 8, P-value = 0.010) in this data set. GLAPA only
weakly confirmed such deregulation (rank = 170, P-
value1 = 0.07, P-value2 = 0.08).
Finally, we analyzed pathways involving E2F transcription
factors which play a key role in tumor progression and in
particular in breast cancer [25]. In fact, alterations in E2Fs
increase cell proliferation and render cells insensitive to
antigrowth signals [24]. RS and GSEA revealed significant
deregulations of E2F3 (rank = 32, P-value = 0.014) and
REN_E2F1_TARGETS (rank = 54, P-value = 0.031) signa-
tures respectively, while GLAPA confirmed only weakly
the result of RS (rank = 136, P-value1 = 0.063, P-value2 =
0.136).
Lung cancer
We compared the three methods in NSCLC data set of
patients with adenocarcinoma and squamous phenotypes
[12]. To this end, we measured the alteration of Myc onco-
gene in this data set. The Myc oncogene family encodes a
group of nuclear phosphoproteins that plays a role in cell
growth and in the development of human tumors. In par-
ticular, overexpression and amplification of Myc family
Table 6: Deregulation of the five oncogenes as measured by the three methods.
RS GLAPA GSEA
Pathway Size Rank P-value Rank P-value1 P-value2 Rank P-value
Myc_up 119 60 0.083 997 0.005 0.831 7 0.000
Myc_down 129 1099 0.629 242 0.006 0.199 6 0.000
Ras_up 195 1181 0.726 842 0.007 0.998 6 0.019
Ras_down 153 439 0.442 1216 0.004 0.991 5 0.006
E2F3_up 138 35 0.088 79 0.012 0.472 4 0.000
E2F3_down 160 994 0.619 1111 0.016 0.965 10 0.008
Src_up 28 182 0.186 1409 0.018 0.513 17 0.060
Src_down 45 41 0.104 781 0.019 0.303 9 0.032
β-catenin_up 43 231 0.198 1588 0.063 0.952 4 0.006
β-catenin_down 55 87 0.105 495 0.016 0.211 6 0.011BMC Bioinformatics 2009, 10:275 http://www.biomedcentral.com/1471-2105/10/275
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members have been reported in the majority of Small Cell
Lung Cancer (SCLC) and in a subset of Non-Small Cell
Lung Cancers (NSCLC) [26]. GLAPA was able to detect a
strong deregulation of the Myc signature (rank = 5, p-
value1 < 10-3, p-value2 = 0.008) and this evidence was
confirmed by RS (rank = 80, p-value = 0.029). Also GSEA
detected a deep deregulation of this oncogene, highlight-
ing a different signature of this gene (YEN_MYC_WT, rank
= 21, p-value = 0.016).
Previous work has linked Ras activation with the develop-
ment of adenocarcinomas of the lung [10]. RS and GLAPA
shown similar abilities in highlighting Ras deregulation in
this data set providing significant ranks of 51 (p-value =
0.03) and 61 (p-value1 < 0.001, p-value2 = 0.089) respec-
tively.
Finally, we measured alterations of cell cycle pathway
which is known to be involved in NSCLC [27]. RS and
GSEA detected cell cycle alterations in the current experi-
mental conditions. In fact, RS highlighted
SERUM_FIBROBLAST_CELLCYCLE (rank = 7, p-value =
0.018) and GSEA detected CELL_CYCLE_REGULATOR
(rank = 1, p-value1, p-value2 < 10-3). These findings were
only weakly confirmed by GLAPA. In fact, in the first case
GLAPA reported (rank = 317, p-value1 < 0.001, p-value2
= 0.472) and in the second one reported (rank = 178, p-
value1 < 0.001, p-value2 = 0.060).
Variation in rankings across methods
To further quantify the similarity of the enrichment esti-
mates across the three methods we compare the overlaps
of the ranks of gene sets across the three methods. These
comparisons are made pairwise. For each pair of methods
for example GSEA versus GLAPA we compute the overlap
of the two rank ordered gene sets as a function of the
number of gene sets considered. In the four plots in Figure
1 the x-axis is the number of top gene sets considered and
the y-axis is the overlap. This is displayed for the P53,
hypoxia, beast cancer, and lung cancer data in Figures 1(a,
b, c, d). The different pairwise comparisons are displayed
in different colors for the three pairwise comparisons.
From this picture it is obvious that there is a greater simi-
larity between RS and GLAPA in evaluating pathway
deregulation and this similarity is uniform across exam-
ples. For example, among the top 250 enriched gene sets
in the P53 example the overlap between RS and GLAPA is
60% (p-value = 0 by Fisher's exact test) of gene sets in
common, while this number reduces to 30% (p-value = 0)
comparing GLAPA with GSEA.
In summary the rankings overlap significantly across the
three methods but the similarity between GLAPA and RS
is considerably greater.
Associative versus predictive scores
In this subsection we focus on GLAPA versus RS. Although
these two methods provide similar rankings the statistic
computed and therefore the significance of this statistic
are different. In the case of GLAPA the statistic, the cross-
validation error, is predictive - how well do the genes in
the gene set predict the phenotype of interest, for example
hypoxic condition. In RS setting is that of classical two
sample hypothesis testing where we measure a set of
means and ask if these means are different under the null
hypothesis that the two conditions or phenotypes are
identical. The predictive statistic or requirement is much
more stringent than the associative case. The following
simple example illustrates this: consider a pathway com-
posed of a single gene x and suppose that the distribution
of expression levels of this gene is xI ~ No(0, 1) in pheno-
type I (control) and xII ~ No(ε, 1) in phenotype II (case)
with ε > 0 arbitrarily small. Given enough observations a
two sample t-test or any other reasonable hypothesis test
will provide strong evidence for rejecting the null hypoth-
esis - these two phenotypes have the same means. How-
ever, the classification accuracy of any classifier, even the
optimal Bayes classifier will be arbitrarily close to 50%.
This phenomenon is not just theoretical but we see this in
our analyses of the various data sets. To highlight this we
examined the overlap of significant gene sets obtained by
GLAPA and RS in three of the examples, P53, breast can-
cer, and lung cancer. We did not include hypoxia due its
the small sample size. In the case of RS significant gene
sets were those with p-values less than 0.05 and in the case
of GLAPA both p-values were required to be less than
0.05. We consider the gene sets found significant by
GLAPA to be predictive and the ones found significant by
RS associative. Table 7 lists the number of significant gene
sets via both methods and their overlap. The overlap
between the methods is substantial and significant by
Fisher's exact test. See Additional file 9, Additional file 10
and Additional file 11 for this list of gene sets. An interest-
ing example of a gene set that is found to predictive in
addition to being associative by GLAPA and RS respec-
tively is the P53 pathway in breast cancer. This suggests
that this pathway is predictive of recurrence and the effect
size of the deregulation measured by the associative test is
large. This would be an important pathway to further
study. Another example of this is the case of alterations of
cell cycle pathways that we report in the lung cancer sec-
tion where pathways were detected by RS and GSEA but
failed the second p-value test of GLAPA suggesting that
they are weakly predictive.
Discussion and conclusion
Many methods have been developed in the last few years
to assess the differential enrichment of sets of genes [2-9]
highlighting the importance of pathway analysis in theBMC Bioinformatics 2009, 10:275 http://www.biomedcentral.com/1471-2105/10/275
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study of complex diseases, and, in particular, in oncology.
In this paper we have compared four of these techniques
which belong to two different classes of methods. Fisher's
exact test [3], GSEA [2], RS [8,9] are associative methods
which quantify the deregulation of a gene set comparing
the distributions of the expression levels of the genes in
the gene set in the two phenotypic conditions analyzed.
GLAPA [7] is a predictive method which measures dereg-
ulation by assessing the prediction accuracy of the pheno-
type of new subjects by using the expression levels of the
genes in the gene set. The performances of these methods
as well as their intrinsic properties have been highlighted
and characterized by analyzing the methods in different
experimental conditions. Numerous aspects have
emerged by our comparative study. Concerning the meth-
ods analyzed, the simulation studies confirm that Fisher's
exact test is considerably worse than the other three meth-
ods as it is unable to detect gene sets with modest deregu-
lation. On the contrary, RS and GSEA are able to highlight
subtle alterations. The former does not suffer of the simul-
Overlaps of the ranks of gene sets across the three methods in a) P53, b) hypoxia, c) breast cancer and d) lung cancer data sets Figure 1
Overlaps of the ranks of gene sets across the three methods in a) P53, b) hypoxia, c) breast cancer and d) lung 
cancer data sets. x-axis represents the number of top gene sets considered and y-axis represents the overlap in each pair-
wise comparison.
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Table 7: Number of statistical significant gene sets highlighted by 
RS with p-value < 0.05 and by GLAPA with p-value1, p-value2 < 
0.05.
Dataset RS GLAPA Common gene sets
P53 91 35 27
Breast 77 47 27
Lung 340 76 31BMC Bioinformatics 2009, 10:275 http://www.biomedcentral.com/1471-2105/10/275
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taneous presence of up and down regulated genes in the
gene set, while the latter is able to detect the true deregu-
lation even whether, as in the case of oncogenic pathways,
the phenotypic distinction is characterized by a wide vari-
ety of altered pathways. Although the performances of
these two approaches are comparable, GSEA does come
with easy to use code and a graphical interface as well as a
compendium of gene sets which in many respects trumps
statistical rigor. GLAPA deserves a separate discussion as it
assesses deregulation through a predictive statistics. We
have made explicit the deep difference existing between
associative and predictive statistics. This method is more
conservative and is able to detect deregulation when the
difference between the two phenotypic conditions is
marked. Such property has been confirmed by the analysis
of the method on breast and lung cancer data sets in
which GLAPA revealed the alteration of pathways and
oncogenes relevant for these pathologies.
Concerning the gene sets adopted in our study, we have
shown that using core sets, composed of different signa-
tures of the same gene or pathways thought to be corre-
lated in the data set, makes the analysis less sensitive to
the noise embedded in the data. The reason for consider-
ing core sets is that gene sets are constructed under a vari-
ety of contexts and conditions and looking at a group of
sets helps average out this variation. This aspect is evident
in P53 and hypoxia data sets.
The purpose of our comparative study was to provide sug-
gestions for users of gene set methods regarding which
method to use under which condition. The results do not
allow to determine univocally the most suitable method
as one method does not always outperform the others.
However, we can make some general recommendations.
In terms of significance and the type of statistic used,
GSEA and RS are more similar and provide comparable
information. In this context if there are no computational
constraints we suggest the use of GSEA especially if one
suspects that the data consists of many deregulated path-
ways as was the case in oncogenic perturbation example.
We recommend running both GSEA and GLAPA or RS
and GLAPA in tandem as they provide complementary
information. In the case of developing drug targets or
when it is important to have a measure of the predictive
accuracy on individuals rather than global differences in
distributions between the two phenotypes GLAPA is well
suited. Also of fundamental importance in all these meth-
ods is which gene sets one is using and also the consider-
ation of splitting gene sets into up and down regulated
subsets. This was seen in the P53 example and also is the
case in the oncogenic perturbation example. We also sug-
gest that users of these methods look carefully at the out-
comes of these enrichment studies and realize that
variation in significance across methods often is reflective
of biological variation in that there may be many under-
lying pathways or sets of genes that are differentially
expressed in the data set.
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